<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Exp Ther Med</journal-id><journal-id journal-id-type="iso-abbrev">Exp Ther Med</journal-id><journal-id journal-id-type="publisher-id">ETM</journal-id><journal-title-group><journal-title>Experimental and Therapeutic Medicine</journal-title></journal-title-group><issn pub-type="ppub">1792-0981</issn><issn pub-type="epub">1792-1015</issn><publisher><publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27284304</article-id><article-id pub-id-type="pmc">4887799</article-id><article-id pub-id-type="doi">10.3892/etm.2016.3199</article-id><article-id pub-id-type="publisher-id">ETM-0-0-3199</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Study on the inflammatory intervention of erythropoietin on NEC</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>QI</surname><given-names>WEIBIN</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-3199">1</xref><xref rid="c1-etm-0-0-3199" ref-type="corresp"/></contrib><contrib contrib-type="author"><name><surname>SHEN</surname><given-names>QIONG</given-names></name><xref ref-type="aff" rid="af2-etm-0-0-3199">2</xref></contrib><contrib contrib-type="author"><name><surname>ZHANG</surname><given-names>LIN</given-names></name><xref ref-type="aff" rid="af3-etm-0-0-3199">3</xref><xref rid="c2-etm-0-0-3199" ref-type="corresp"/></contrib><contrib contrib-type="author"><name><surname>HAN</surname><given-names>LI-PING</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-3199">1</xref></contrib><contrib contrib-type="author"><name><surname>WANG</surname><given-names>SUMIN</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-3199">1</xref></contrib></contrib-group><aff id="af1-etm-0-0-3199"><label>1</label>Department of Neonatology, The Fourth Hospital of Shijiazhuang, Shijiazhuang, Hebei 050011, P.R. China</aff><aff id="af2-etm-0-0-3199"><label>2</label>Department of Gynaecology and Obstetrics, Armed Police Hebei Corps Hospital, Shijiazhuang, Hebei 050081, P.R. China</aff><aff id="af3-etm-0-0-3199"><label>3</label>Department of Pediatrics, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China</aff><author-notes><corresp id="c1-etm-0-0-3199"><italic>Correspondence to</italic>: Dr Weibin Qi, Department of Neonatology, The Fourth Hospital of Shijiazhuang, 206 Zhongshan East Road, Shijiazhuang, Hebei 050011, P.R. China, E-mail: <email>weibin_qi@163.com</email></corresp><corresp id="c2-etm-0-0-3199">Dr Lin Zhang, Department of Pediatrics, The Third Hospital of Hebei Medical University, 16 Weiming Street, Shijiazhuang, Hebei 050000, P.R. China, E-mail: <email>linzhang_9@163.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>6</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>29</day><month>3</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>29</day><month>3</month><year>2016</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="epub"/>. --><volume>11</volume><issue>6</issue><fpage>2221</fpage><lpage>2224</lpage><history><date date-type="received"><day>13</day><month>11</month><year>2015</year></date><date date-type="accepted"><day>29</day><month>3</month><year>2016</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Qi et al.</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license></permissions><abstract><p>The aim of this study was to investigate the effect of erythropoietin (EPO) on the inflammatory response and the mechanism analysis of the &#x003a4;oll-like receptor 4 (TLR4)/nuclear factor-&#x003ba;B (NF-&#x003ba;B) signaling pathway of NEC. A total of 94 patients with necrotizing enterocolitis (NEC) were randomly divided into the control (42 cases) and observation (52 cases) groups, The control group received the standard medical treatment plan, whereas for the observation group this treatment plan was combined with the application of recombinant EPO for intramuscular injection treatment. The clinical effect was subsequently compared. The results showed that the complication and death rates in the observation group were significantly lower than those in the control group with statistically significant differences (P&#x0003c;0.05). Following treatments, the levels of tumor necrosis factor-&#x003b1; (TNF-&#x003b1;) and interleukin (IL)-6 in the observation group were significantly lower than those in the control group. The expression levels of mRNA of TLR4 and NF-&#x003ba;B in the observation group were significantly lower than those in the control group, with statistically significant differences (P&#x0003c;0.05). In summary, EPO was able to reduce the levels of inflammatory response of TNF-&#x003b1; and IL-6 through the TLR4/NF-&#x003ba;B signaling pathway, and improve the NEC, thus providing a basis for the clinical treatment of NEC.</p></abstract><kwd-group><kwd>erythropoietin</kwd><kwd>necrotizing enteroolitis</kwd><kwd>inflammatory reaction</kwd><kwd>&#x003a4;oll-like receptor 4/nuclear factor-&#x003ba;B signaling pathway</kwd><kwd>tumor necrosis factor-&#x003b1;</kwd><kwd>interleukin-6</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>The main biological effect of erythropoietin (EPO) has been manifested through the promotion of proliferation, differentiation, and maturation of erythroid progenitor cells, as well as an increase in the number of red blood cells in the circulation (<xref rid="b1-etm-0-0-3199" ref-type="bibr">1</xref>). Therefore, EPO is widely used in the treatment of neonatal, cancer and renal anemia. Recent findings have shown that EPO and EPO receptors are widely distributed (<xref rid="b2-etm-0-0-3199" ref-type="bibr">2</xref>). They are expressed in a variety of non-hematopoietic tissues, and are also equipped with a variety of non-hematopoietic biological effects, such as angiogenic promotion, anti-inflammation, anti-apoptosis and neuroprotection and are considered to be a systemic protective cytokine (<xref rid="b2-etm-0-0-3199" ref-type="bibr">2</xref>). It has been found that breast milk contains EPO, and intestines of neonatals contain EPO receptors, which indicate that EPO may play an important physiological role in the growth and development of the gastrointestinal tract (<xref rid="b3-etm-0-0-3199" ref-type="bibr">3</xref>). Previous studies suggested that the recombinant EPO in a mouse model of neonatal necrotizing enterocolitis (NEC) can reduce the inflammatory reaction and improve NEC injury (<xref rid="b4-etm-0-0-3199" ref-type="bibr">4</xref>).</p><p>The aim of the present study was to examine the clinical effect of EPO on the inflammatory response and possible mechanism of action of the TLR4/NF-&#x003ba;B signaling pathway, through clinical trials, to provide a new basis for the clinical treatment of NEC.</p></sec><sec sec-type="subjects|methods"><title>Patients and methods</title><sec><title/><sec><title>Patients</title><p>In total, 94 cases diagnosed with NEC between August, 2013 and August, 2015 were selected for the present study. The diagnosis of NEC conformed to the standard of the American Society for Parenteral and Enteral Nutrition (<xref rid="b5-etm-0-0-3199" ref-type="bibr">5</xref>). The study was approved by the Ethics Committee of The Fourth Hospital of Shijiazhuang. Informed consent from the guardian, according to the order of admission was obtained. The 94 patients with NEC were randomly divided into the control (42 cases) and observation (52 cases) groups. A comparison of the baseline information identified that differences were statistically significant (P&#x0003c;0.05). <xref rid="tI-etm-0-0-3199" ref-type="table">Table I</xref> shows that NEC staging was performed in accordance with the standard of Bell's NEC staging.</p></sec><sec><title>Research methods</title><p>The control group were given the standard medical treatment plan, which included fasting, no hydration, gastrointestinal decompression, parenteral nutrition, selection of sensitive antibiotics, early stage, full weight, appropriate amount of rehydration, maintainance of gastrointestinal tissue perfusion, correct anemia, electrolyte disorder, acid-base imbalance, blood pressure, heart rate, blood glucose and respiratory support. The abdominal X-ray was regularly performed to observe changes of the disease. If the disease was not relieved or continued to deteriorate with conservative treatment of internal medicine, surgical resection was subsequently performed. The observation group was treated with a combined application of recombinant EPO (National Medical License no. S20000007, 2,000 IU/dose; Shandong Kexing Bioproducts Co., Ltd., Shandong, China) for intramuscular injection, at a dose of 200 IU/kg, twice a week for a total of 1 week. Any allergic reaction or other adverse reactions were observed closely.</p></sec><sec><title>Observation index and detection technology</title><p>The differences of the complication and death rates were compared between the two groups, including levels of tumor necrosis factor-&#x003b1; (TNF-&#x003b1;), interleukin (IL)-6 and the mRNA expression levels of &#x003a4;oll-like receptor 4 (TLR4) and nuclear factor-&#x003ba;B (NF-&#x003ba;B). Venous blood (5 ml) was collected on an empty stomach and centrifuged at 2,800 g at high speed and the supernatant was removed after 5 min. TNF-&#x003b1; and IL-6 kits were purchased from Shanghai J&#x00026;M Co. Ltd. (Shanghai, China). The ELISA method was applied and the experiment was performed according to the manufacturer's instructions. The expression of mRNA for TLR4 and NF-&#x003ba;B was detected by quantitative polymerase chain reaction (TaqMan probe method) and the SYBR-Green I staining method (Shinegene, Shanghai, China), respectively. Subsequently, the standard curves of the target genes (<italic>TLR4</italic> and <italic>NF-&#x003ba;B</italic>) and housekeeping genes (<italic>GAPDH</italic>) were created. By means of the standard curves, the expression of the target and housekeeping genes in the samples was quantified. The relative expression amount of TLR4 and NF-&#x003ba;B in each group was determined after correction of the housekeeping genes.</p></sec><sec><title>Statistical analysis</title><p>SPSS 20.0 statistical software (IBM SPSS, Armonk, NY, USA) was applied to determine statistical analysis. Measurement data were presented as mean &#x000b1; standard deviation. The t-test was applied for comparisons between groups and the Kruskal-Wallis H was applied to make pathological scoring of intestinal tissues. Enumeration data were presented as a percentage (%). The &#x003c7;<sup>2</sup> test was applied for comparisons between groups. P&#x0003c;0.05 was considered to indicate a statistically significant difference.</p></sec></sec></sec><sec sec-type="results"><title>Results</title><sec><title/><sec><title>Comparison of complication and death rates</title><p>The complication and death rates in the observation group were significantly lower than those in the control group and differences were statistically significant (P&#x0003c;0.05) (<xref rid="tI-etm-0-0-3199" ref-type="table">Tables I</xref> and <xref rid="tII-etm-0-0-3199" ref-type="table">II</xref>).</p></sec><sec><title>Comparison of the expression levels of TNF-&#x003b1; and IL-6</title><p>Prior to intervention, differences between the two groups with regard to the levels of TNF-&#x003b1; and IL-6 were not statistically significant (P&#x0003e;0.05). After intervention, the levels of TNF-&#x003b1; and IL-6 of the control group were increased while the levels of the observation group were reduced. The levels of the observation group were significantly lower than those of the control group and differences were statistically significant (P&#x0003c;0.05) (<xref rid="tIII-etm-0-0-3199" ref-type="table">Table III</xref>).</p></sec><sec><title>Comparison of mRNA expression levels of TLR4 and NF-&#x003ba;B</title><p>Prior to intervention, differences between the two groups with regard to the mRNA expression levels of TLR4 and NF-&#x003ba;B were not statistically significant (P&#x0003e;0.05). After intervention, the mRNA expression levels of TLR4 and NF-&#x003ba;B in the two groups were significantly decreased and those in the observation were lower than those in the control group. Differences were statistically significant (P&#x0003c;0.05) (<xref rid="tIV-etm-0-0-3199" ref-type="table">Table IV</xref>).</p></sec></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>EPO is a glycoprotein with a molecular weight of 30.4 kDa. In the fetus period, it is mainly synthesized by liver and post birth, and the kidney. Ledbetter and others (<xref rid="b6-etm-0-0-3199" ref-type="bibr">6</xref>) found from a retrospective study that the incidence of NEC on premature infants with EPO injection was significantly lower than that of infants not treated with EPO (<xref rid="b7-etm-0-0-3199" ref-type="bibr">7</xref>). To study the protective mechanism of EPO on NEC, Kumral and others (<xref rid="b8-etm-0-0-3199" ref-type="bibr">8</xref>) used EOP to preprocess hypoxia reperfusion NEC mice (EPO 750 U/kg/week, intraperitoneal injection in 3 shots for 2 weeks). On day 15, the animals were exposed to 100% CO<sub>2</sub> for anoxia for 5 min, followed by reoxygenation with 100% O<sub>2</sub> for 10 min, and then executed after 4 h. Compared to the result of the experimental group, the level of nitric oxide in the EPO pretreatment group was significantly decreased, and the injury of the intestinal tissue was reduced, indicating that EPO retarted the occurrence of NEC in mice by inhibiting the excessive production of nitric oxide (<xref rid="b9-etm-0-0-3199" ref-type="bibr">9</xref>). Akisu and others (<xref rid="b10-etm-0-0-3199" ref-type="bibr">10</xref>) used the same method to study the role of EPO in the production of intestinal malondialdehyde (MDA) and platelet activating factor (PAF). Their study results showed that although EPO cannot inhibit the production of PAF in the necrotic intestine tissues resulting from hypoxia reperfusion, it can significantly decrease the MDA content in the intestinal tissues of mice, indicating that EPO may play a role in the prevention and treatment of NEC by inhibiting the lipid peroxidation mediated by oxygen-free radicals (<xref rid="b11-etm-0-0-3199" ref-type="bibr">11</xref>). Shiou and others (<xref rid="b12-etm-0-0-3199" ref-type="bibr">12</xref>) have shown that supplementing EPO via the intestinal tract upregulated the expression of ZO-1, a tight junction protein in the enterocytes of NEC mice, which protected the intestinal mucosal barrier function (<xref rid="b13-etm-0-0-3199" ref-type="bibr">13</xref>). Halpern and Denning (<xref rid="b7-etm-0-0-3199" ref-type="bibr">7</xref>) used 3-day SD mice and constructed a NEC model after artificial feeding and hypoxia cold stimulation, and intervened by supplementing EPO of a similar physiological concentration as breast milk through the intestinal tract. Their study results showed that EPO downregulated the expression of TLR4 in intestinal tissues of mice and inhibited the inflammatory cascade reaction, reduced the intestinal tissue damage, retarted the malignant progression, and finally reduced the occurrence of bacterial translocation (<xref rid="b3-etm-0-0-3199" ref-type="bibr">3</xref>,<xref rid="b12-etm-0-0-3199" ref-type="bibr">12</xref>).</p><p>The role of TLR4 in the pathogenesis of NEC has aroused increasing attention (<xref rid="b14-etm-0-0-3199" ref-type="bibr">14</xref>). The expression of TLR4 in normal intestinal epithelial cells is low, whereas that in NEC children and animal models is high. The high expression of TLR4 appeared even before NEC tissue injury. High-risk factors of NEC, including premature birth, artificial feeding, hypoxia ischemia, and bacterial factors can lead to an increase of TLR4 expression (<xref rid="b4-etm-0-0-3199" ref-type="bibr">4</xref>). The role of TLR4 in the pathogenesis of NEC was mainly associated with inflammation and repair (<xref rid="b15-etm-0-0-3199" ref-type="bibr">15</xref>). Activated TLR4 can activate NF-&#x003ba;B, and induce the upregulated expression of downstream inflammatory cytokines. NF-&#x003ba;B in intestinal tissues removed from animal models and NEC children showed a sustained high expression, while the expression of the inflammatory cytokines in the lower reaches, such as TNF-&#x003b1;, IL-6 and IL-8, also increased. A large number of inflammatory mediators leads to damage in the intestinal epithelial cells and mucosal defense mechanism, which would ultimately develop into NEC. Inhibiting of the TLR4 pathway can significantly reduce the expression of inflammatory mediators, alleviate macrophage infiltration, and reduce the occurrence of bacterial translocation (<xref rid="b16-etm-0-0-3199" ref-type="bibr">16</xref>,<xref rid="b17-etm-0-0-3199" ref-type="bibr">17</xref>).</p><p>Results of the present study show that the complication and death rates in the observation group were lower than those in the control group. The levels of TNF-&#x003b1; and IL-6 in the observation group were significantly lower than those in the control group. The mRNA expression levels of TLR4 and NF-&#x003ba;B in the observation group were significantly lower than those in the control group, and differences were statistically significant. In conclusion, EPO can reduce the levels of inflammatory response of TNF-&#x003b1; and IL-6 through the TLR4/NF-&#x003ba;B signaling pathway and improve NEC, thereby providing a basis for the clinical treatment of NEC.</p></sec></body><back><ref-list><title>References</title><ref id="b1-etm-0-0-3199"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cody</surname><given-names>JD</given-names></name><name><surname>Hodson</surname><given-names>EM</given-names></name></person-group><article-title>Recombinant human erythropoietin versus placebo or no treatment for the anaemia of chronic kidney disease in people not requiring dialysis</article-title><source>Cochrane Database Syst Rev</source><volume>1</volume><fpage>CD003266</fpage><year>2016</year><pub-id pub-id-type="pmid">26790135</pub-id></element-citation></ref><ref id="b2-etm-0-0-3199"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez</surname><given-names>E</given-names></name><name><surname>Beuch&#x000e9;e</surname><given-names>A</given-names></name><name><surname>Truffert</surname><given-names>P</given-names></name><name><surname>Pouvreau</surname><given-names>N</given-names></name><name><surname>Patkai</surname><given-names>J</given-names></name><name><surname>Baud</surname><given-names>O</given-names></name><name><surname>Boubred</surname><given-names>F</given-names></name><name><surname>Flamant</surname><given-names>C</given-names></name><name><surname>Jarreau</surname><given-names>PH</given-names></name></person-group><article-title>Recombinant human erythropoietin in neonates: Guidelines for clinical practice from the French Society of Neonatology</article-title><source>Arch Pediatr</source><volume>22</volume><fpage>1092</fpage><lpage>1097</lpage><year>2015</year><comment>(In French)</comment><pub-id pub-id-type="doi">10.1016/j.arcped.2015.07.001</pub-id><pub-id pub-id-type="pmid">26320680</pub-id></element-citation></ref><ref id="b3-etm-0-0-3199"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Shiou</surname><given-names>SR</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Westerhoff</surname><given-names>M</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Petrof</surname><given-names>EO</given-names></name><name><surname>Claud</surname><given-names>EC</given-names></name></person-group><article-title>Erythropoietin protects epithelial cells from excessive autophagy and apoptosis in experimental neonatal necrotizing enterocolitis</article-title><source>PLoS One</source><volume>8</volume><fpage>e69620</fpage><year>2013</year><pub-id pub-id-type="doi">10.1371/journal.pone.0069620</pub-id><pub-id pub-id-type="pmid">23936061</pub-id></element-citation></ref><ref id="b4-etm-0-0-3199"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nanthakumar</surname><given-names>N</given-names></name><name><surname>Meng</surname><given-names>D</given-names></name><name><surname>Goldstein</surname><given-names>AM</given-names></name><etal/></person-group><article-title>The mechanism of excessive intestinal inflammation in necrotizing enterocolitis: An immature innate immune response</article-title><source>PLoS One</source><volume>6</volume><fpage>e17776</fpage><year>2011</year><pub-id pub-id-type="doi">10.1371/journal.pone.0017776</pub-id><pub-id pub-id-type="pmid">21445298</pub-id></element-citation></ref><ref id="b5-etm-0-0-3199"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fallon</surname><given-names>EM</given-names></name><name><surname>Nehra</surname><given-names>D</given-names></name><name><surname>Potemkin</surname><given-names>AK</given-names></name><name><surname>Gura</surname><given-names>KM</given-names></name><name><surname>Simpser</surname><given-names>E</given-names></name><name><surname>Compher</surname><given-names>C</given-names></name></person-group><article-title>A.S.P.E.N. clinical guidelines: Nutrition support of neonatal patients at risk for necrotizing enterocolitis</article-title><source>J Parenter Enteral Nutr</source><volume>36</volume><fpage>506</fpage><lpage>523</lpage><year>2012</year><pub-id pub-id-type="doi">10.1177/0148607112449651</pub-id></element-citation></ref><ref id="b6-etm-0-0-3199"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ledbetter</surname><given-names>DJ</given-names></name><name><surname>Joyce</surname><given-names>AE</given-names></name><name><surname>Dame</surname><given-names>C</given-names></name><name><surname>Christensen</surname><given-names>RD</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>DeMarco</surname><given-names>V</given-names></name><name><surname>Juul</surname><given-names>SE</given-names></name></person-group><article-title>Erythropoietin acts as a trophic factor in neonatal rat intestine</article-title><source>Gut</source><volume>49</volume><fpage>182</fpage><lpage>189</lpage><year>2001</year><pub-id pub-id-type="doi">10.1136/gut.49.2.182</pub-id><pub-id pub-id-type="pmid">11454792</pub-id></element-citation></ref><ref id="b7-etm-0-0-3199"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halpern</surname><given-names>MD</given-names></name><name><surname>Denning</surname><given-names>PW</given-names></name></person-group><article-title>The role of intestinal epithelial barrier function in the development of NEC</article-title><source>Tissue Barriers</source><volume>3</volume><fpage>e1000707</fpage><year>2015</year><pub-id pub-id-type="doi">10.1080/21688370.2014.1000707</pub-id><pub-id pub-id-type="pmid">25927016</pub-id></element-citation></ref><ref id="b8-etm-0-0-3199"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumral</surname><given-names>A</given-names></name><name><surname>Baskin</surname><given-names>H</given-names></name><name><surname>Duman</surname><given-names>N</given-names></name><name><surname>Yilmaz</surname><given-names>O</given-names></name><name><surname>Tatli</surname><given-names>M</given-names></name><name><surname>Ozer</surname><given-names>E</given-names></name><name><surname>G&#x000f6;kmen</surname><given-names>N</given-names></name><name><surname>Genc</surname><given-names>S</given-names></name><name><surname>Ozkan</surname><given-names>H</given-names></name></person-group><article-title>Erythropoietin protects against necrotizing enterocolitis of newborn rats by the inhibiting nitric oxide formation</article-title><source>Biol Neonate</source><volume>84</volume><fpage>325</fpage><lpage>329</lpage><year>2003</year><pub-id pub-id-type="doi">10.1159/000073642</pub-id><pub-id pub-id-type="pmid">14593244</pub-id></element-citation></ref><ref id="b9-etm-0-0-3199"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fauch&#x000e8;re</surname><given-names>JC</given-names></name><name><surname>Koller</surname><given-names>BM</given-names></name><name><surname>Tschopp</surname><given-names>A</given-names></name><name><surname>Dame</surname><given-names>C</given-names></name><name><surname>Ruegger</surname><given-names>C</given-names></name><name><surname>Bucher</surname><given-names>HU</given-names></name></person-group><article-title>Swiss Erythropoietin Neuroprotection Trial Group: Safety of early high-dose recombinant erythropoietin for neuroprotection in very preterm infants</article-title><source>J Pediatr</source><volume>167</volume><fpage>52</fpage><lpage>7</lpage><comment>e1&#x02013;3</comment><year>2015</year><pub-id pub-id-type="doi">10.1016/j.jpeds.2015.02.052</pub-id><pub-id pub-id-type="pmid">25863661</pub-id></element-citation></ref><ref id="b10-etm-0-0-3199"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akisu</surname><given-names>M</given-names></name><name><surname>Baka</surname><given-names>M</given-names></name><name><surname>Huseyinov</surname><given-names>A</given-names></name><name><surname>Kultursay</surname><given-names>N</given-names></name></person-group><article-title>The role of dietary supplementation with L-glutamine in inflammatory mediator release and intestinal injury in hypoxia/reoxygenation-induced experimental necrotizing enterocolitis</article-title><source>Ann Nutr Metab</source><volume>47</volume><fpage>262</fpage><lpage>266</lpage><year>2003</year><pub-id pub-id-type="doi">10.1159/000072398</pub-id><pub-id pub-id-type="pmid">14520021</pub-id></element-citation></ref><ref id="b11-etm-0-0-3199"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seikku</surname><given-names>L</given-names></name><name><surname>Rahkonen</surname><given-names>L</given-names></name><name><surname>Tikkanen</surname><given-names>M</given-names></name><name><surname>H&#x000e4;m&#x000e4;l&#x000e4;inen</surname><given-names>E</given-names></name><name><surname>Rahkonen</surname><given-names>P</given-names></name><name><surname>Andersson</surname><given-names>S</given-names></name><name><surname>Teramo</surname><given-names>K</given-names></name><name><surname>Paavonen</surname><given-names>J</given-names></name><name><surname>Stefanovic</surname><given-names>V</given-names></name></person-group><article-title>Amniotic fluid erythropoietin and neonatal outcome in pregnancies complicated by intrauterine growth restriction before 34 gestational weeks</article-title><source>Acta Obstet Gynecol Scand</source><volume>94</volume><fpage>288</fpage><lpage>294</lpage><year>2015</year><pub-id pub-id-type="doi">10.1111/aogs.12553</pub-id><pub-id pub-id-type="pmid">25484184</pub-id></element-citation></ref><ref id="b12-etm-0-0-3199"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiou</surname><given-names>SR</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Ciancio</surname><given-names>MJ</given-names></name><name><surname>Petrof</surname><given-names>EO</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Claud</surname><given-names>EC</given-names></name></person-group><article-title>Erythropoietin protects intestinal epithelial barrier function and lowers the incidence of experimental neonatal necrotizing enterocolitis</article-title><source>J Biol Chem</source><volume>286</volume><fpage>12123</fpage><lpage>12132</lpage><year>2011</year><pub-id pub-id-type="doi">10.1074/jbc.M110.154625</pub-id><pub-id pub-id-type="pmid">21262973</pub-id></element-citation></ref><ref id="b13-etm-0-0-3199"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name></person-group><article-title>A meta-analysis of the protectiveeffect of recombinant human erythropoietin (rhEPO) for neuro-development in preterm infants</article-title><source>Cell Biochem Biophys</source><volume>71</volume><fpage>795</fpage><lpage>802</lpage><year>2015</year><pub-id pub-id-type="doi">10.1007/s12013-014-0265-1</pub-id><pub-id pub-id-type="pmid">25300689</pub-id></element-citation></ref><ref id="b14-etm-0-0-3199"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>M</given-names></name><name><surname>Takeda</surname><given-names>K</given-names></name></person-group><article-title>Current views of toll-like receptor signaling pathways</article-title><source>Gastroenterol Res Pract</source><volume>2010</volume><fpage>240365</fpage><year>2010</year><pub-id pub-id-type="doi">10.1155/2010/240365</pub-id><pub-id pub-id-type="pmid">21197425</pub-id></element-citation></ref><ref id="b15-etm-0-0-3199"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>KL</given-names></name><name><surname>Wong</surname><given-names>KF</given-names></name><name><surname>Luk</surname><given-names>JM</given-names></name></person-group><article-title>Role of LPS/CD14/TLR4- mediated inflammation in necrotizing enterocolitis: Pathogenesis and therapeutic implications</article-title><source>World J Gastroenterol</source><volume>15</volume><fpage>4745</fpage><lpage>4752</lpage><year>2009</year><pub-id pub-id-type="doi">10.3748/wjg.15.4745</pub-id><pub-id pub-id-type="pmid">19824106</pub-id></element-citation></ref><ref id="b16-etm-0-0-3199"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhee</surname><given-names>SH</given-names></name></person-group><article-title>Basic and translational understandings of microbial recognition by toll-like receptors in the intestine</article-title><source>J Neurogastroenterol Motil</source><volume>17</volume><fpage>28</fpage><lpage>34</lpage><year>2011</year><pub-id pub-id-type="doi">10.5056/jnm.2011.17.1.28</pub-id><pub-id pub-id-type="pmid">21369489</pub-id></element-citation></ref><ref id="b17-etm-0-0-3199"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sodhi</surname><given-names>CP</given-names></name><name><surname>Shi</surname><given-names>XH</given-names></name><name><surname>Richardson</surname><given-names>WM</given-names></name><name><surname>Grant</surname><given-names>ZS</given-names></name><name><surname>Shapiro</surname><given-names>RA</given-names></name><name><surname>Prindle</surname><given-names>T</given-names><suffix>Jr</suffix></name><name><surname>Branca</surname><given-names>M</given-names></name><name><surname>Russo</surname><given-names>A</given-names></name><name><surname>Gribar</surname><given-names>SC</given-names></name><name><surname>Ma</surname><given-names>C</given-names></name><etal/></person-group><article-title>Toll-like receptor-4 inhibits enterocyte proliferation via impaired &#x003b2;-catenin signaling in necrotizing enterocolitis</article-title><source>Gastroenterology</source><volume>138</volume><fpage>185</fpage><lpage>196</lpage><year>2010</year><pub-id pub-id-type="doi">10.1053/j.gastro.2009.09.045</pub-id><pub-id pub-id-type="pmid">19786028</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="tI-etm-0-0-3199" orientation="portrait" position="float"><label>Table I.</label><caption><p>Comparison of baseline information between the control and observation groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Group</th><th align="center" valign="bottom" rowspan="1" colspan="1">Control group, n=42</th><th align="center" valign="bottom" rowspan="1" colspan="1">Observation group, n=52</th><th align="center" valign="bottom" rowspan="1" colspan="1">t (&#x003c7;<sup>2</sup> test)</th><th align="center" valign="bottom" rowspan="1" colspan="1">P-value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Male/female</td><td align="center" valign="top" rowspan="1" colspan="1">23/19</td><td align="center" valign="top" rowspan="1" colspan="1">28/24</td><td align="center" valign="top" rowspan="1" colspan="1">0.008</td><td align="center" valign="top" rowspan="1" colspan="1">0.929</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age, day</td><td align="center" valign="top" rowspan="1" colspan="1">13.4&#x000b1;2.5</td><td align="center" valign="top" rowspan="1" colspan="1">12.5&#x000b1;2.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.624</td><td align="center" valign="top" rowspan="1" colspan="1">0.337</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Weight, kg</td><td align="center" valign="top" rowspan="1" colspan="1">2.2&#x000b1;0.6</td><td align="center" valign="top" rowspan="1" colspan="1">2.1&#x000b1;0.5</td><td align="center" valign="top" rowspan="1" colspan="1">0.421</td><td align="center" valign="top" rowspan="1" colspan="1">0.564</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">1 min Apgar score</td><td align="center" valign="top" rowspan="1" colspan="1">8.2&#x000b1;0.7</td><td align="center" valign="top" rowspan="1" colspan="1">8.3&#x000b1;0.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.519</td><td align="center" valign="top" rowspan="1" colspan="1">0.768</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NEC staging</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;I</td><td align="center" valign="top" rowspan="1" colspan="1">6 (14.3)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (11.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.920</td><td align="center" valign="top" rowspan="1" colspan="1">0.631</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;II</td><td align="center" valign="top" rowspan="1" colspan="1">26 (61.9)</td><td align="center" valign="top" rowspan="1" colspan="1">37 (71.2)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;III</td><td align="center" valign="top" rowspan="1" colspan="1">10 (23.8)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (17.3)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Premature birth</td><td align="center" valign="top" rowspan="1" colspan="1">25 (59.5)</td><td align="center" valign="top" rowspan="1" colspan="1">28 (53.8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.305</td><td align="center" valign="top" rowspan="1" colspan="1">0.581</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Caesarean section</td><td align="center" valign="top" rowspan="1" colspan="1">20 (47.6)</td><td align="center" valign="top" rowspan="1" colspan="1">23 (44.2)</td><td align="center" valign="top" rowspan="1" colspan="1">0.107</td><td align="center" valign="top" rowspan="1" colspan="1">0.743</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Breast feeding</td><td align="center" valign="top" rowspan="1" colspan="1">29 (69.0)</td><td align="center" valign="top" rowspan="1" colspan="1">33 (63.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.373</td><td align="center" valign="top" rowspan="1" colspan="1">0.830</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Milk powder feeding</td><td align="center" valign="top" rowspan="1" colspan="1">6 (14.3)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (15.4)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Breast + milk powder feeding</td><td align="center" valign="top" rowspan="1" colspan="1">7 (16.7)</td><td align="center" valign="top" rowspan="1" colspan="1">11 (21.2)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hemoglobin, g/l</td><td align="center" valign="top" rowspan="1" colspan="1">185.6&#x000b1;13.7</td><td align="center" valign="top" rowspan="1" colspan="1">184.2&#x000b1;14.5</td><td align="center" valign="top" rowspan="1" colspan="1">0.967</td><td align="center" valign="top" rowspan="1" colspan="1">0.325</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hematocrit</td><td align="center" valign="top" rowspan="1" colspan="1">62.4&#x000b1;1.7</td><td align="center" valign="top" rowspan="1" colspan="1">62.5&#x000b1;1.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.624</td><td align="center" valign="top" rowspan="1" colspan="1">0.857</td></tr></tbody></table></table-wrap><table-wrap id="tII-etm-0-0-3199" orientation="portrait" position="float"><label>Table II.</label><caption><p>Comparison of complication and death rates.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Group</th><th align="center" valign="bottom" rowspan="1" colspan="1">Cases</th><th align="center" valign="bottom" rowspan="1" colspan="1">Septicemia</th><th align="center" valign="bottom" rowspan="1" colspan="1">Acute intestinal perforation</th><th align="center" valign="bottom" rowspan="1" colspan="1">Infectious peritonitis</th><th align="center" valign="bottom" rowspan="1" colspan="1">Others</th><th align="center" valign="bottom" rowspan="1" colspan="1">Complication rate</th><th align="center" valign="bottom" rowspan="1" colspan="1">Death rate</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Control group</td><td align="center" valign="top" rowspan="1" colspan="1">42</td><td align="center" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1">6</td><td align="center" valign="top" rowspan="1" colspan="1">6</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">21 (50.0)</td><td align="center" valign="top" rowspan="1" colspan="1">11 (26.2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Observation group</td><td align="center" valign="top" rowspan="1" colspan="1">52</td><td align="center" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">16 (30.8)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (9.6)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x003c7;<sup>2</sup> test</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">3.868</td><td align="center" valign="top" rowspan="1" colspan="1">4.519</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">P-value</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.049</td><td align="center" valign="top" rowspan="1" colspan="1">0.034</td></tr></tbody></table></table-wrap><table-wrap id="tIII-etm-0-0-3199" orientation="portrait" position="float"><label>Table III.</label><caption><p>Comparison of the levels of TNF-&#x003b1; and IL-6 between the observation and control groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" valign="bottom" colspan="2" rowspan="1">TNF-&#x003b1;, ng/l</th><th align="center" valign="bottom" colspan="2" rowspan="1">IL-6, ng/l</th></tr><tr><th rowspan="1" colspan="1"/><th align="center" valign="bottom" colspan="2" rowspan="1"><hr/></th><th align="center" valign="bottom" colspan="2" rowspan="1"><hr/></th></tr><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Group</th><th align="center" valign="bottom" rowspan="1" colspan="1">Pre-intervention</th><th align="center" valign="bottom" rowspan="1" colspan="1">Post-intervention</th><th align="center" valign="bottom" rowspan="1" colspan="1">Pre-intervention</th><th align="center" valign="bottom" rowspan="1" colspan="1">Post-intervention</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="center" valign="top" rowspan="1" colspan="1">56.7&#x000b1;6.4</td><td align="center" valign="top" rowspan="1" colspan="1">78.4&#x000b1;10.2</td><td align="center" valign="top" rowspan="1" colspan="1">241.3&#x000b1;36.9</td><td align="center" valign="top" rowspan="1" colspan="1">287.5&#x000b1;48.7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Observation</td><td align="center" valign="top" rowspan="1" colspan="1">61.2&#x000b1;6.8</td><td align="center" valign="top" rowspan="1" colspan="1">32.5&#x000b1;4.8</td><td align="center" valign="top" rowspan="1" colspan="1">259.6&#x000b1;42.3</td><td align="center" valign="top" rowspan="1" colspan="1">143.2&#x000b1;32.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">t-test</td><td align="center" valign="top" rowspan="1" colspan="1">0.529</td><td align="center" valign="top" rowspan="1" colspan="1">6.498</td><td align="center" valign="top" rowspan="1" colspan="1">0.629</td><td align="center" valign="top" rowspan="1" colspan="1">6.213</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">P-value</td><td align="center" valign="top" rowspan="1" colspan="1">0.423</td><td align="center" valign="top" rowspan="1" colspan="1">0.012</td><td align="center" valign="top" rowspan="1" colspan="1">0.415</td><td align="center" valign="top" rowspan="1" colspan="1">0.018</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-etm-0-0-3199"><p>TNF-&#x003b1;, tumor necrosis factor-&#x003b1;; IL-6, interleukin-6.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tIV-etm-0-0-3199" orientation="portrait" position="float"><label>Table IV.</label><caption><p>Comparison of mRNA expression levels of TLR4 and NF-&#x003ba;B.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" valign="bottom" colspan="2" rowspan="1">TLR4</th><th align="center" valign="bottom" colspan="2" rowspan="1">NF-&#x003ba;B</th></tr><tr><th rowspan="1" colspan="1"/><th align="center" valign="bottom" colspan="2" rowspan="1"><hr/></th><th align="center" valign="bottom" colspan="2" rowspan="1"><hr/></th></tr><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Group</th><th align="center" valign="bottom" rowspan="1" colspan="1">Pre-intervention</th><th align="center" valign="bottom" rowspan="1" colspan="1">Post-intervention</th><th align="center" valign="bottom" rowspan="1" colspan="1">Pre-intervention</th><th align="center" valign="bottom" rowspan="1" colspan="1">Post-intervention</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="center" valign="top" rowspan="1" colspan="1">3.3&#x000b1;0.5</td><td align="center" valign="top" rowspan="1" colspan="1">2.6&#x000b1;0.3</td><td align="center" valign="top" rowspan="1" colspan="1">2.4&#x000b1;0.6</td><td align="center" valign="top" rowspan="1" colspan="1">1.8&#x000b1;0.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Observation</td><td align="center" valign="top" rowspan="1" colspan="1">3.6&#x000b1;0.7</td><td align="center" valign="top" rowspan="1" colspan="1">1.2&#x000b1;0.4</td><td align="center" valign="top" rowspan="1" colspan="1">2.7&#x000b1;0.5</td><td align="center" valign="top" rowspan="1" colspan="1">0.7&#x000b1;0.1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">t-test</td><td align="center" valign="top" rowspan="1" colspan="1">0.924</td><td align="center" valign="top" rowspan="1" colspan="1">7.436</td><td align="center" valign="top" rowspan="1" colspan="1">0.825</td><td align="center" valign="top" rowspan="1" colspan="1">8.125</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">P-value</td><td align="center" valign="top" rowspan="1" colspan="1">0.721</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">0.364</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn id="tfn2-etm-0-0-3199"><p>TLR4, &#x003a4;oll-like receptor 4; NF-&#x003ba;B, nuclear factor-&#x003ba;B.</p></fn></table-wrap-foot></table-wrap></floats-group></article>